Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Corporation

In a report released yesterday, Derek Archila from Wells Fargo maintained a Hold rating on Incyte, with a price target of $101.00. The company’s sh...

Incyte (INCY) Receives a Hold from Wells Fargo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lipocine (LPCN), Viridian Therapeutics (VRDN) and Incyte (INCY). ...

Analysts Offer Insights on Healthcare Companies: Lipocine (LPCN), Viridian Therapeutics (VRDN) and Incyte (INCY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY), Sanofi (SNYNF) and Johnson & Johnso...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Sanofi (OtherSNYNF) and Johnson & Johnson (JNJ)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Incyte (INCY) and Veradigm (MDRX) with bullish senti...

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Veradigm (OtherMDRX)

Incyte ($INCY) announced an update on their ongoing clinical study. The Phase 1 trial “A Phase 1, Open-Label, Multicenter Study of INCA036978 in Pa...

Incyte Expands Blood Cancer Pipeline With New Early Stage INCA036978 Trial

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report), Incyte...

Current Quarter	$1.22	Next Quarter	$1.57
Current Year	$6.53	Next Year	$7.87
QoQ Growth	+28.7%	YoY Growth	+20.5%
3Y EPS CAGR	-66.6%	Target Price	$109.14
Consensus	Buy	Upside	+15.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INCY	$94.90	-1.07%	488.60K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INCY	$94.90	-1.1%	488.60K
3
4
5
6

INCY

INCY

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Incyte Corporation Data in Excel

Get Incyte Corporation Data in Excel